Eton Pharmaceuticals Inc. (ETON)
$61.96
$1.53
(2.53%)
As on 02-Sep-2026 16:05EDT
Market cap
$1,709 Mln
Revenue (TTM)
$106 Mln
P/E Ratio
153.3
P/B Ratio
38.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.4 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
86
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.4
-
Face value
--
-
Shares outstanding
28,583,135
7 Years Aggregate
CFO
$-48.68 Mln
EBITDA
$-60.10 Mln
Net Profit
$-84.02 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eton Pharmaceuticals (ETON)
| 266.4 | 33.5 | 116.0 | 257.9 | 138.5 | 63.8 | -- |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Eton Pharmaceuticals (ETON)
| 27.0 | 201.4 | 55.3 | -34.3 | -47.2 | 12.9 | 17.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eton Pharmaceuticals (ETON)
|
62.0 | 1,708.7 | 105.6 | 12.7 | 2.5 | 34.9 | 153.3 | 38.5 |
| 18.1 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 209.9 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.5 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 110.4 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 24.7 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 7.8 | 5,233.7 | 7,430.4 | 452.5 | 17.6 | 7 | 10 | 0.8 | |
| 286.9 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 69.7 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 131.0 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Eton Pharmaceuticals (ETON)
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle... for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Read more
-
President, CEO & Director
Mr. Sean E. Brynjelsen
-
President, CEO & Director
Mr. Sean E. Brynjelsen
-
Headquarters
Deer Park, IL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Eton Pharmaceuticals (ETON)
What is the current share price of Eton Pharmaceuticals Inc (ETON) Today?
The share price of Eton Pharmaceuticals Inc (ETON) is $61.96 (NASDAQ) as of 02-Sep-2026 16:05 EDT. Eton Pharmaceuticals Inc (ETON) has given a return of 138.45% in the last 3 years.
What is the current PB & PE ratio of Eton Pharmaceuticals Inc (ETON)?
The P/E ratio of Eton Pharmaceuticals Inc (ETON) is 153.28 times as on 28-Aug-2026, a 311 premium to its peers’ median range of 37.32 times.
The P/B ratio of Eton Pharmaceuticals Inc (ETON) is 38.45 times as on 28-Aug-2026, a 396 premium to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-98.89 |
17.40 |
2024 |
-91.06 |
14.25 |
2023 |
-120.45 |
7.28 |
2022 |
-8.03 |
5.54 |
2021 |
-56.96 |
6.32 |
What is the 52 Week High and Low of Eton Pharmaceuticals Inc (ETON)?
The 52-week high and low of Eton Pharmaceuticals Inc (ETON) are Rs 66.37 and Rs 14.27 as of 03-Sep-2026.
What is the market cap of Eton Pharmaceuticals Inc (ETON)?
Eton Pharmaceuticals Inc (ETON) has a market capitalisation of $ 1,709 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Eton Pharmaceuticals Inc (ETON)?
Before investing in Eton Pharmaceuticals Inc (ETON), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.